Ilja Bot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilja Bot has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Christian U Blank
Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication- Christian U. Blank
Leiden University Medical Center, Leiden, The Netherlands
1 shared publication Dieta Brandsma
Department of Neurology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication- Dieta Brandsma
Department of Neuro-Oncology, Netherlands Cancer Institute , Amsterdam
1 shared publication Willem Boogerd
Department of Neurology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- 13 March 2013
- Published by BMJ in Practical Neurology
- Vol. 13 (4) , 278-280
Neurological immune-related adverse events of ipilimumab
Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain–Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.
- 13 March 2013
- Published by BMJ in Practical Neurology
- Vol. 13 (4) , 278-280
Neurological immune-related adverse events of ipilimumab
Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain–Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.
- 18 April 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (9) , 1976-1978
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab
- 18 April 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (9) , 1976-1978
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab